Ignite Creation Date:
2025-12-26 @ 5:19 PM
Ignite Modification Date:
2026-03-11 @ 9:09 PM
Study NCT ID:
NCT01716806
Status:
COMPLETED
Last Update Posted:
2024-06-11
First Post:
2012-10-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Sponsor:
Seagen Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Antibody-Drug Conjugate | View |
| None | Antibodies, Monoclonal | View |
| None | Hematologic Diseases | View |
| None | Hodgkin Disease | View |
| None | Antigens, CD30 | View |
| None | Lymphoma | View |
| None | monomethylauristatin E | View |
| None | Drug Therapy | View |
| None | CD30-expression | View |
| None | PTCL | View |
| None | Seattle Genetics | View |